Stay updated with breaking news from Edward Kaye. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a 30-day window to purchase up to an additional 15% of the shares in the public offering.
The gene-based drug reduced the frequency of seizures by 43 percent to 85 percent in 34 patients who participated in four early-stage studies.
– Data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome – – End of Phase 1/2a study results and OLE data from patients receiving ongoing treatment; Analyses...
The development of RNA therapeutics for epilepsy will "change everything" because it opens up entirely new druggable targets and address the underlying causes of epilepsy, experts say.
